HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

AbstractBACKGROUND:
The CpG island methylator phenotype (CIMP), characterised by widespread promoter methylation, is associated with microsatellite instability (MSI) and BRAF mutation in colorectal cancer. The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain.
METHODS:
Utilising 649 colon cancers (stage I-IV) in two independent cohort studies, we quantified DNA methylation in eight CIMP-specific promoters (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) as well as CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14, and WRN by using MethyLight technology. We examined MSI, KRAS and BRAF status. Cox proportional hazard models computed hazard ratios (HRs) for colon cancer-specific and overall mortalities, adjusting for patient characteristics and tumoral molecular features.
RESULTS:
After adjustment for other predictors of patient survival, patients with CIMP-high cancers (126 (19%) tumours with >or=6/8 methylated CIMP-specific promoters) experienced a significantly low colon cancer-specific mortality (multivariate HR 0.44, 95% confidence interval (CI) 0.22 to 0.88), whereas the BRAF mutation was significantly associated with a high cancer-specific mortality (multivariate HR 1.97, 95% CI 1.13 to 3.42). A trend toward a low cancer-specific mortality was observed for MSI-high tumours (multivariate HR 0.70, 95% CI 0.36 to 1.37). In stratified analyses, CIMP-high tumours were associated with a significant reduction in colon cancer-specific mortality, regardless of both MSI and BRAF status. The relation between CIMP-high and lower mortality appeared to be consistent across all stages. KRAS mutation was unrelated to prognostic significance.
CONCLUSION:
CIMP-high appears to be an independent predictor of a low colon cancer-specific mortality, while BRAF mutation is associated with a high colon cancer-specific mortality.
AuthorsShuji Ogino, Katsuhiko Nosho, Gregory J Kirkner, Takako Kawasaki, Jeffrey A Meyerhardt, Massimo Loda, Edward L Giovannucci, Charles S Fuchs
JournalGut (Gut) Vol. 58 Issue 1 Pg. 90-6 (Jan 2009) ISSN: 1468-3288 [Electronic] England
PMID18832519 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA, Neoplasm
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
Topics
  • Aged
  • Colonic Neoplasms (genetics, mortality, pathology)
  • CpG Islands (genetics)
  • DNA Methylation
  • DNA, Neoplasm (genetics)
  • Epidemiologic Methods
  • Epigenesis, Genetic
  • Female
  • Humans
  • Male
  • Microsatellite Instability
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Phenotype
  • Prognosis
  • Proto-Oncogene Proteins B-raf (genetics)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: